Acquisition Targeting Rare Bleeding Disorders Worth Up to $27 Billion: U.S. Pharma Expands Blood Disorder Pipeline

US biotech company Incyte Corporation (INCY) has entered into a stock purchase agreement valued at up to $2 billion—approximately ₩2.7 trillion—including about $1.25 billion in cash and up to $750 million in revenue‐based milestones to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics.

The transaction is expected to close in Q3 2026, subject to expiration of the Hart-Scott-Rodino waiting period and customary closing conditions. Incyte plans to record a one-time R&D charge of roughly $1.25 billion (about ₩1.7 trillion) in its Q3 and full-year 2026 results.

The acquisition will add VGA039—a Phase III monoclonal antibody targeting protein S for bleeding disorders such as von Willebrand disease—to Incyte’s hematology portfolio.

In its late-April release of first-quarter 2026 results, Incyte reported net sales from its hematology and oncology portfolio of $204 million, a 116% increase year-over-year, and reaffirmed its full-year 2026 revenue and expense guidance, emphasizing continued pipeline investment.

In early May, the FDA approved Jakafi XR, Incyte’s once-daily, extended-release formulation of the myelofibrosis treatment Jakafi, bolstering dosage options and extending the life cycle of its flagship hematologic cancer therapy.

Based in Wilmington, Delaware, Incyte is focused on treatments for myelofibrosis (Jakafi), dermatologic conditions (the JAK inhibitor Opzelura), hematologic cancers, immunologic skin disorders and autoimmune diseases. The company’s pipeline spans three core areas—hematology, oncology and inflammation/autoimmunity—targeting rare blood cancers, solid tumors and immune diseases. This latest move to acquire a bleeding-disorder asset aligns with its strategy to strengthen its hematology franchise.